JP6505682B2 - ヘテロ環式化合物およびそれらの使用方法 - Google Patents

ヘテロ環式化合物およびそれらの使用方法 Download PDF

Info

Publication number
JP6505682B2
JP6505682B2 JP2016524633A JP2016524633A JP6505682B2 JP 6505682 B2 JP6505682 B2 JP 6505682B2 JP 2016524633 A JP2016524633 A JP 2016524633A JP 2016524633 A JP2016524633 A JP 2016524633A JP 6505682 B2 JP6505682 B2 JP 6505682B2
Authority
JP
Japan
Prior art keywords
nhc
phenyl
alkyl
alkynyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016524633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525093A5 (enExample
JP2016525093A (ja
Inventor
デビット マッカシー,トーマス
デビット マッカシー,トーマス
ネイラー,アラン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013902513A external-priority patent/AU2013902513A0/en
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016525093A publication Critical patent/JP2016525093A/ja
Publication of JP2016525093A5 publication Critical patent/JP2016525093A5/ja
Application granted granted Critical
Publication of JP6505682B2 publication Critical patent/JP6505682B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016524633A 2013-07-08 2014-07-08 ヘテロ環式化合物およびそれらの使用方法 Expired - Fee Related JP6505682B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013902513 2013-07-08
AU2013902513A AU2013902513A0 (en) 2013-07-08 Method of treatment or prophylaxis
PCT/AU2014/050116 WO2015003223A1 (en) 2013-07-08 2014-07-08 Heterocyclic compounds and methods of their use

Publications (3)

Publication Number Publication Date
JP2016525093A JP2016525093A (ja) 2016-08-22
JP2016525093A5 JP2016525093A5 (enExample) 2017-08-17
JP6505682B2 true JP6505682B2 (ja) 2019-04-24

Family

ID=52279233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524633A Expired - Fee Related JP6505682B2 (ja) 2013-07-08 2014-07-08 ヘテロ環式化合物およびそれらの使用方法

Country Status (9)

Country Link
US (1) US9714224B2 (enExample)
EP (1) EP3019477B1 (enExample)
JP (1) JP6505682B2 (enExample)
CN (1) CN105358532B (enExample)
ES (1) ES2883155T3 (enExample)
NZ (1) NZ630908A (enExample)
PL (1) PL3019477T3 (enExample)
PT (1) PT3019477T (enExample)
WO (1) WO2015003223A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6232384B2 (ja) 2012-01-06 2017-11-15 ノバルティス アーゲー 複素環式化合物およびその使用方法
ES2898635T3 (es) * 2015-03-12 2022-03-08 Novartis Ag Compuestos heterocíclicos y métodos para su uso
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
KR102132761B1 (ko) * 2017-06-09 2020-07-17 산동 단홍 파머수티컬 컴퍼니., 리미티드. At2r 수용체 길항제로서의 카르복시산 유도체
US11485725B2 (en) 2017-12-15 2022-11-01 Auransa Inc. Derivatives of piperlongumine and uses thereof
US11384097B2 (en) 2018-06-19 2022-07-12 Zhejiang Hisun Pharmaceutical Co., Ltd. Tetrahydroisoquinoline derivative, preparation method therefor and use thereof
WO2020012266A1 (en) * 2018-07-12 2020-01-16 Novartis Ag Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase
WO2020228436A1 (zh) 2019-05-10 2020-11-19 浙江海正药业股份有限公司 芳环或杂芳环类衍生物及其制备方法和用途
CN111620816B (zh) * 2020-05-27 2023-06-02 上海赛默罗生物科技有限公司 螺桨烷类衍生物、其制备方法、药物组合物和用途
CN113880825B (zh) * 2020-07-01 2025-03-14 浙江海正药业股份有限公司 四氢异喹啉类衍生物的盐、其制备方法及其医药应用
CN111777555B (zh) * 2020-09-04 2020-12-01 上海赛默罗生物科技有限公司 脂肪环烷衍生物、其制备方法、药物组合物和其应用
AU2022318349B2 (en) 2021-07-30 2025-12-18 Confo Therapeutics N.V. Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling
CN117603088A (zh) * 2023-10-28 2024-02-27 广东工业大学 一种基于氨基酸乙酯的芳香醛席夫碱及其在不对称烷基化中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55127373A (en) * 1979-03-26 1980-10-02 Takeda Chem Ind Ltd Tetrahydroisoquinoline compound and its preparation
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US6649606B1 (en) * 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
WO2006055951A2 (en) * 2004-11-19 2006-05-26 Portola Pharmaceuticals, Inc. Tetrahydroisoquinolines as factor xa inhibitors
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
JP5230595B2 (ja) 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
ES2560327T3 (es) * 2010-01-19 2016-02-18 Novartis Ag Métodos y composiciones para una velocidad de conducción nerviosa mejorada
NZ605444A (en) 2010-07-21 2015-06-26 Spinifex Pharm Pty Ltd Salt and solvates of a tetrahydroisoquinoline derivative
JP6232384B2 (ja) 2012-01-06 2017-11-15 ノバルティス アーゲー 複素環式化合物およびその使用方法
JP6258867B2 (ja) 2012-01-25 2018-01-10 ノバルティス アーゲー 複素環式化合物およびその使用方法
EP2807171B1 (en) 2012-01-25 2020-08-12 Novartis AG Heterocyclic compounds and methods for their use

Also Published As

Publication number Publication date
US9714224B2 (en) 2017-07-25
EP3019477B1 (en) 2021-05-26
ES2883155T3 (es) 2021-12-07
JP2016525093A (ja) 2016-08-22
CN105358532B (zh) 2019-07-23
EP3019477A1 (en) 2016-05-18
CN105358532A (zh) 2016-02-24
WO2015003223A1 (en) 2015-01-15
PT3019477T (pt) 2021-08-20
PL3019477T3 (pl) 2021-11-22
EP3019477A4 (en) 2017-01-11
US20160145213A1 (en) 2016-05-26
NZ630908A (en) 2017-08-25

Similar Documents

Publication Publication Date Title
EP3019477B1 (en) Heterocyclic compounds and methods of their use
JP6258867B2 (ja) 複素環式化合物およびその使用方法
JP6073926B2 (ja) 複素環式化合物およびその使用方法
JP6232384B2 (ja) 複素環式化合物およびその使用方法
AU2013202978A1 (en) Heterocyclic compounds and methods for their use
JP2018501320A (ja) アンジオテンシンii2型拮抗薬としてのピロリジン誘導体
HK1208219A1 (en) (e)-n-(2-amino-phenyl)-3-{1-[4-(1-methyl-1h-pyrazol-4-yl)-benzenesulfonyl]-1h-pyrrol-3-yl}-acrylamide tosylate salt
CN107466293B (zh) 杂环化合物及其应用方法
HK1201531B (en) Heterocyclic compounds and methods for their use
HK1201533B (en) Heterocyclic compounds and methods for their use
HK1201521B (en) Heterocyclic compounds and methods for their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170705

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190327

R150 Certificate of patent or registration of utility model

Ref document number: 6505682

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees